Aller au contenu
  • HOME
  • About Us
    • Our Mission
    • Our Team
    • Our Investors
    • Our Partners
  • Technology
  • Pipeline
    • Overview
    • Influenza – OVX836
    • Coronavirus – OVX033
  • News
    • Press Releases
    • Media Coverage
    • Publications
    • Events
  • Careers
  • Contact
  • HOME
  • About Us
    • Our Mission
    • Our Team
    • Our Investors
    • Our Partners
  • Technology
  • Pipeline
    • Overview
    • Influenza – OVX836
    • Coronavirus – OVX033
  • News
    • Press Releases
    • Media Coverage
    • Publications
    • Events
  • Careers
  • Contact

Archives de la catégorie : Media

New influenza vaccine strategies aim to enhance protection with T-cell responses

Publié parMarianne Duparcmai 6, 2024février 7, 2025Publié dans2024, MediaÉtiquettes : Media

Vaccine Developers Leverage mRNA and Other Powerful Technologies

Publié parMarianne Duparcmai 3, 2024mai 3, 2024Publié dans2024, MediaÉtiquettes : Media

France launches trial for a groundbreaking broad-spectrum coronavirus vaccine

Publié parMarianne Duparcfévrier 16, 2024février 16, 2024Publié dans2024, MediaÉtiquettes : Media

2024 J.P. Morgan Healthcare Conference: key takeaways from the largest biotech gathering of the year

Publié parOsi Vaxjanvier 18, 2024janvier 18, 2024Publié dans2024, MediaÉtiquettes : Media

Vers un vaccin efficace contre tous les variants du SARS-CoV2 ?

Publié parMarianne Duparcseptembre 15, 2023septembre 26, 2023Publié dans2023, MediaÉtiquettes : Media

Les quatre domaines d’excellence de la French Tech

Publié parMarianne Duparcseptembre 4, 2023septembre 26, 2023Publié dans2023, MediaÉtiquettes : Media

Universal Flu Vaccine Candidate Shows Promise in Mid-Stage Trial — Efficacy in range of NIH target, exploratory analysis finds

Publié parMarianne Duparcaoût 2, 2023août 22, 2023Publié dans2023, MediaÉtiquettes : Media

OVX-033 vaccine exhibits broad protection against SARS-CoV-2 in preclinical models

Publié parMarianne Duparcjuillet 11, 2023juillet 17, 2023Publié dans2023, MediaÉtiquettes : Media

Race for universal flu vaccine ramps up as Osivax kicks off Phase IIa trial

Publié parMarianne Duparcjuin 16, 2023juin 20, 2023Publié dans2023, MediaÉtiquettes : Media

En bref : Cellprothera, Osivax, Confo Therapeutics, Daiichi Sankyo

Publié parMarianne Duparcavril 3, 2023juin 20, 2023Publié dans2023, MediaÉtiquettes : 2023, Media

Pagination des publications

1 2 3 4 Articles plus anciens

Our Address

Osivax​​ France

Swely Bâtiment C « Slam »
​70 Rue Saint Jean Dieu
69007 Lyon
France

​​Phone: +33 (0)9 70 30 13 80
Mail: contact@osivax.com

Osivax Belgium

Bâtiment B 
​7 Rue des Chasseurs Ardennais 
4031 Angleur 
Belgique

Linkedin Youtube Twitter

Get in Touch

We would be happy to answer all your questions.
Just send us your message by using our Contact Form or Email.

CONTACT US
  • Privacy Policy
  • Legal Notice
  • Conflict of Interest Policy

All rights reserved by Osivax – 2023  

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of all the cookies. Read more about our "Privacy Policy"
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Toujours activé
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDuréeDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
Enregistrer & appliquer